GTB-3550
GT Biopharma
[]
gt biopharma presents preclinical data demonstrating second-generation cd19 targeting tri-specific killer engager (trike(r)) driving robust nk cell function against b cell malignancies at eha 2022 congress 
We provide a balanced view on small cap biotech equities.